Access to Medicines

2014 – IP and Access to Essential Medicines – A Tenuous Link

Intellectual Property and Access to Essential Medicines: A Tenuous Link?

According to the World Health Organization,1 essential medicines are medicines that satisfy priority health care needs of a population, and they are selected with regard to disease prevalence, safety, efficacy, and comparative cost-effectiveness. In addition, they are intended to be available in functioning health systems at all times in adequate amounts, in appropriate dosage forms, with assured quality, and at affordable prices.

Calvin W.L. Ho, Klaus M. Leisinger

Erschienen: 2014

Download > [de]

2013 – APBN V17 No6 Feature Access to Medicines

Access to Medicines and Corporate Social Responsibilities of the Pharmaceutical Industry

Research-based pharmaceutical companies have the role of developing, producing and distributing innovative medicines that can save lives, cure diseases and improve quality of life and must do so in a profitable way.

Klaus M. Leisinger

Erschienen: 2013

Download > [de]

2012 – Access to Medicines Business and Professional Ethics Journal

Poverty, Disease, and Medicines in Low- and Middle-Income Countries: The Roles and Responsibilities of Pharmaceutical Corporations

Providing access to medicines and health care is one of the most challenging issues facing society today. In this paper the author highlights some of the complexities of the health value chain as well as the problems that the world’s poor have in terms of access to medical care and medicines.

Klaus M. Leisinger

Erschienen: 2012

Download > [en]

2012 -Cambridge Quarterly of Healthcare Ethics

Access to Healthcare and the Pharmaceutical Sector

Health is higher on the international agenda than ever before, and improving the health of poor people is a central issue in development. Poor people suffer from far higher levels of ill health, mortality, and malnutrition than do those better off, and their inadequate health is one of the factors keeping them poor or for their being poor in the first place.

Klaus M. Leisinger, Karin Schmitt

Erschienen: 2012

Download > [de]

2012 Access to Medicines Business & Professional Ethics Journal

Poverty, Disease, and Medicines in Low- and Middle-Income Countries

Providing access to medicines and health care is one of the most challenging issues facing society today. In this paper the author highlights some of the complexities of the health value chain as well as the problems that the world’s poor have in terms of access to medical care and medicines.

Klaus M. Leisinger

Erschienen: 31.01.2012

Download > [en]

2012 – Southern Med Review Improving Access to Medicines

Corporate Responsibilities in Context

More than two billion people in low- and middle-income countries (LMIC) lack adequate access to essential medicines. In this paper, we make strong public health, human rights and economic arguments for improving access to medicines in LMIC and discuss the different roles and responsibilities of key stakeholders, including national governments, the international community, and non-governmental organizations (NGOs).

Klaus Michael Leisinger, Laura Faden Garabedian, Anita Katharina Wagner

Erschienen: 2012

Download > [de]

2011 – Unternehmensverantwortung bei Marktversagen

Der Zugang von in Armut lebenden Patienten zu lebensnotwendigen Medikamenten als Multi- Stakeholder-Problematik

Im vorliegenden Zusammenhang geht es um die Beantwortung der Frage, wofür ein Pharma-Unternehmen nach dem heutigen Stand der Wissenschaft und der gesellschaftlichen Erwartungen Verantwortung trägt.

Klaus M. Leisinger

Erschienen: 2011

Download > [de]

2010 – Cambridge Quarterly Lifting all Boats

Access to Medicines and the Pharmaceutical Sector

Despite the substantial progress that has been achieved in human development over the past three decades, measured in higher per capita incomes, improved life expectancy at birth, lower infant and child mortality, higher literacy rates, and increased school enrolment, there is no reason for complacency..

Klaus M. Leisinger

Erschienen: 2010

Download > [en]

2009 – Journal of Business Ethics – Corporate Responsibilities for Access to medicines

Today there is a growing wave of demands being placed upon the pharmaceutical industry to contribute to improved access to medicines for poor patients in the developing countries.

Klaus M. Leisinger

Erschienen: 2008

Download > [en]

2005 – Corporate Social responsibility of Phamaceutical Industry Business Ethics Quarterly

In recent years society has come to expect more from the “sociallyresponsible” company and the global HIV/AIDS pandemic in particular has resulted in some critics saying that the “Big Pharma” companies have not been living up to their social responsibilities.

Klaus M. Leisinger

Erschienen: 2005

Download > [en]